INmune Bio, Inc.
INMB
$7.30
-$0.20-2.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.65% | 23.77% | -24.08% | 11.60% | -31.13% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -60.00% | -37.50% | -29.41% | -24.44% |
| Total Other Non-Cash Items | 18.16% | 2.21% | -26.85% | 32.10% | -5.32% |
| Change in Net Operating Assets | 123.58% | -205.48% | 756.23% | -129.61% | -43.69% |
| Cash from Operations | 38.04% | -57.64% | 11.41% | -5.48% | -119.82% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 1,149.76% | -96.57% | -20.68% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 353.80% | -121.22% | -24.66% | 619.88% | 0.00% |
| Foreign Exchange rate Adjustments | -107.59% | 242.72% | -634.09% | -133.85% | 303.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 87.45% | -608.66% | -51.00% | 151.46% | -65.06% |